

# Anti-Podoplanin (PDPN) Antibody

Mouse Monoclonal Antibody Catalog # AH13089

### Specification

## Anti-Podoplanin (PDPN) Antibody - Product Information

Application Primary Accession Other Accession Reactivity Host Clonality Isotype WB, IHC-P, IF, FC <u>Q86YL7</u> <u>468675</u> Human Mouse Monoclonal Mouse / IgG1, kappa

### Anti-Podoplanin (PDPN) Antibody - Additional Information

Gene ID 10630

**Other Names** 

Aggrus; Glycoprotein 36 KD; Glycoprotein 36; gp36; GP38; GP40; HT1A1; hT1alpha1; hT1alpha2; Lung type I cell membrane associated glycoprotein; Lung type I cell membrane associated glycoprotein T1A 2; OTS8; PA2.26; Pdpn; Podoplanin; PSEC0003; PSEC0025; T1-alpha; T1A; TIA; TIA2

Application Note <span class ="dilution\_WB">WB~~1:1000</span><br \><span class ="dilution\_IHC-P">IHC-P~~N/A</span><br \><span class ="dilution\_IF">IF~~1:50~200</span><br \><span class ="dilution\_FC">FC~~1:10~50</span>

Format

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Storage

Store at 2 to 8°C.Antibody is stable for 24 months.

Precautions

Anti-Podoplanin (PDPN) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

### Anti-Podoplanin (PDPN) Antibody - Protein Information

Name PDPN {ECO:0000312|EMBL:AAH14668.2}

Function

Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation (PubMed:<a



href="http://www.uniprot.org/citations/14522983" target=" blank">14522983</a>, PubMed:<a href="http://www.uniprot.org/citations/15231832" target=" blank">15231832</a>, PubMed:<a href="http://www.uniprot.org/citations/17222411" target="\_blank">17222411</a>, PubMed:<a href="http://www.uniprot.org/citations/17616532" target="\_blank">17616532</a>, PubMed:<a href="http://www.uniprot.org/citations/18215137" target=" blank">18215137</a>). Interaction with CD9, on the contrary, attenuates platelet aggregation induced by PDPN (PubMed:<a href="http://www.uniprot.org/citations/18541721" target=" blank">18541721</a>). Through MSN or EZR interaction promotes epithelial- mesenchymal transition (EMT) leading to ERZ phosphorylation and triggering RHOA activation leading to cell migration increase and invasiveness (PubMed:<a href="http://www.uniprot.org/citations/17046996" target=" blank">17046996</a>, PubMed:<a href="http://www.uniprot.org/citations/21376833" target=" blank">21376833</a>). Interaction with CD44 promotes directional cell migration in epithelial and tumor cells (PubMed:<a href="http://www.uniprot.org/citations/20962267" target=" blank">20962267</a>). In lymph nodes (LNs), controls fibroblastic reticular cells (FRCs) adhesion to the extracellular matrix (ECM) and contraction of the actomyosin by maintaining ERM proteins (EZR; MSN and RDX) and MYL9 activation through association with unknown transmembrane proteins. Engagement of CLEC1B by PDPN promotes FRCs relaxation by blocking lateral membrane interactions leading to reduction of ERM proteins (EZR; MSN and RDX) and MYL9 activation (By similarity). Through binding with LGALS8 may participate in connection of the lymphatic endothelium to the surrounding extracellular matrix (PubMed:<a href="http://www.uniprot.org/citations/19268462" target=" blank">19268462</a>). In keratinocytes, induces changes in cell morphology showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion (PubMed:<a href="http://www.uniprot.org/citations/15515019" target=" blank">15515019</a>). Controls invadopodia stability and maturation leading to efficient degradation of the extracellular matrix (ECM) in tumor cells through modulation of RHOC activity in order to activate ROCK1/ROCK2 and LIMK1/LIMK2 and inactivation of CFL1 (PubMed: <a href="http://www.uniprot.org/citations/25486435" target=" blank">25486435</a>). Required for normal lung cell proliferation and alveolus formation at birth (By similarity). Does not function as a water channel or as a regulator of aquaporin-type water channels (PubMed:<a href="http://www.uniprot.org/citations/9651190" target=" blank">9651190</a>). Does not have any effect on folic acid or amino acid transport (By similarity).

### **Cellular Location**

[Podoplanin]: Membrane; Single-pass type I membrane protein

{ECO:0000250|UniProtKB:Q62011}. Cell projection, lamellipodium membrane; Single-pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Cell projection, filopodium membrane; Single- pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Cell projection, microvillus membrane; Single- pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Cell projection, ruffle membrane; Single-pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Cell projection, ruffle membrane; Single-pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Cell projection, ruffle membrane; Single-pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Cell projection, ruffle membrane; Single-pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Membrane raft. Apical cell membrane. Basolateral cell membrane. Cell projection, invadopodium. Note=Localized to actin-rich microvilli and plasma membrane projections such as filopodia, lamellipodia and ruffles (By similarity). Association to the lipid rafts is required for PDPN-induced epithelial to mesenchymal transition (EMT) (PubMed:21376833). Colocalizes with CD9 in tetraspanin microdomains (PubMed:18541721). Localized at invadopodium adhesion rings in tumor cell. Association to the lipid rafts is essential for PDPN recruitment to invadopodia and ECM degradation (PubMed:25486435) {ECO:0000250|UniProtKB:Q62011, ECO:0000269|PubMed:18541721, ECO:0000269|PubMed:25486435}

#### **Tissue Location**

Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors and expressed in 25% of early oral squamous cell carcinomas



# Anti-Podoplanin (PDPN) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- <u>Blocking Peptides</u>
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

### Anti-Podoplanin (PDPN) Antibody - Images



Formalin-fixed, paraffin-embedded human Cervix stained with Podoplanin Monoclonal Antibody (PDPN/1433)

### Anti-Podoplanin (PDPN) Antibody - Background

It recognizes a muco-protein of 38-43kDa, which is identified Podoplanin (PDPN). It localizes in stromal cells of peripheral lymphoid tissue and thymic epithelial cells. As a regulator of the lymphatic endothelium, podoplanin probably plays a role in maintaining the unique shape of podocytes. It is selectively expressed in lymphatic endothelium as well as lymphoangiomas, Kaposi sarcomas, and in a subset of angiosarcomas with probable lymphatic differentiation. Recent studies have also shown podoplanin to be a highly sensitive and relatively specific marker for epithelioid mesothelioma. Therefore, it can be used in a panel to distinguish mesotheliomas or mesothelial cells from pulmonary carcinomas.